Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Aethlon Medical Price Performance
NASDAQ:AEMD opened at $1.36 on Monday. The business's 50-day moving average price is $1.15 and its 200 day moving average price is $1.25. Aethlon Medical has a 52-week low of $0.88 and a 52-week high of $5.99.
Aethlon Medical (NASDAQ:AEMD - Get Rating) last announced its earnings results on Tuesday, June 28th. The medical equipment provider reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.13). Aethlon Medical had a negative net margin of 3,542.86% and a negative return on equity of 59.57%. The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $1.02 million. On average, equities analysts forecast that Aethlon Medical will post 0.78 EPS for the current year.
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised Aethlon Medical to a "sell" rating in a research report on Friday.